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a b s t r a c t
This study investigates the impact of early left ventricular (LV)-mechanical unloading on systemic oxida-
tive stress and inflammation in terminal heart failure patients and their impact both on multi organ fail-
ure and on intensive care unit (ICU) stay. Circulating levels of urinary 15-isoprostane-F2t (8-epi-PGF2a)
and pro-inflammatory markers [plasma interleukin (IL)-6, IL-8, and urinary neopterin, a monocyte acti-
vation index] were analyzed in 20 healthy subjects, 22 stable end-stage heart failure (ESHF) patients and
in 23 LV assist device (LVAD) recipients at pre-implant and during first post-LVAD (PL) month. Multi-
organ function was evaluated by total Sequential Organ Failure Assessment (tSOFA) score. In LVAD recip-
ients the levels of oxidative-inflammatory markers and tSOFA score were higher compared to other
groups. After device implantation 8-epi-PGF2a levels were unchanged, while IL-6, and IL-8 levels
increased during first week, and at 1 month returned to pre-implant values, while neopterin levels
increased progressively during LVAD support. The tSOFA score worsened at 1 PL-week with respect to
pre-implant value, but improved at 1 PL-month. The tSOFA score related with IL-6 and IL-8 levels, while
length of ICU stay related with pre-implant IL-6 levels. These data suggest that hemodynamic instability
in terminal HF is associated to worsening of systemic inflammatory and oxidative milieu that do not
improve in the early phase of hemodynamic recovery and LV-unloading by LVAD, affecting multi-organ
function and length of ICU stay. This data stimulate to evaluate the impact of inflammatory signals on
long-term outcome of mechanical circulatory support.
 2012 Elsevier Ltd. All rights reserved.
1. Introduction
In the last decades left ventricular assist device (LVAD) implan-
tation has proven effectiveness in the management of end-stage
heart failure (ESHF) patients [1], not only as bridge to transplant
(BTT), but also as potential destination therapy. An amelioration
of hemodynamic and a decrease of LV filling pressure are more
or less regularly observed since the first hours after LVAD
implantation. Moreover, mechanical LV-unloading by LVAD,
decreasing the LV cavitary pressures, results in the decreased of
wall stress-related signals, which promote favorable changes of
myocardial and peripheral neurohormonal milieu [2], potentially
associated also to cardiac recovery [3].
Clinical studies have shown that many inflammatory cytokines
such as tumor necrosis factor alpha (TNF-a) and interleukin-6
(IL-6) increase in HF patients [4–6], suggesting their important
roles in the underlying pathophysiology of HF [7, 8]. IL-6/C-
reactive protein (CRP) pathway is found more elevated in acute
decompensated HF patients with left ventricular systolic dysfunc-
tion than in patients with preserved LV ejection function [9].
Furthermore, HF is complicated also by oxidative stress, with
elevated levels of lipid peroxides, such as malondialdehyde
(MDA) [10], and alteration of redox state [11], that suggest a link
with inflammatory pathways in the HF pathogenesis [12–14].
In ESHF patients the hemodynamic recovery, amelioration of
neurohormonal milieu, and LV-unloading, by LVAD, might
potentially interrupt the cycle of inflammation and oxidative
stress, contributing to favorable conditions both to outcome of
the mechanical circulatory support (MCS), and to clinical course
during hospitalization. However, the effects of LVAD implant on
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circulating inflammatory cytokines, oxidative stress and redox
state markers in ESHF patients have not yet well investigated.
Moreover, the data about relationship between inflammatory-
oxidative state and clinical course of LVAD patients are sparse.
Thus, the purposes of this study were to: (1) define the
oxidative stress grade and severity of inflammatory milieu in ESHF
patients candidates to LVAD implantation, comparing their pre-
implant levels with those of stable HF patients and healthy sub-
jects, (2) assess the impact of hemodynamic recovery by LVAD
on redox state, oxidative stress, and inflammatory milieu during
first month of LVAD support, and (3) assess whether the dynamic
of multi-organ function and the duration of the stay in intensive
care unit (ICU), reflecting the clinical course of patients, are
affected from oxidative stress and inflammatory markers.
2. Methods
2.1. Patients
Twenty-three ESHF patients underwent LVAD implantation as
BTT were enrolled in the study. In all patients axial continuous-
flow devices were implanted [5 De Bakey-LVADs (MicroMed Tech-
nology, Inc., Houston, TX), 6 Incor-LVADs (Berlin Heart AG) and 12
HeartMateII-LVADs (Thoratec, Pleasanton, CA)].
Twenty-two chronic HF patients, who had been admitted for
routine re-evaluation or for treatment of advanced HF and assigned
to New York Heart Association (NYHA) classes III and IV, were en-
rolled as stable ESHF group.
Twenty healthy subjects with normal LV function (LV ejection
fraction >55%) and no history of cardiovascular events were en-
rolled as control group.
2.2. Study design
Redox state [blood and plasma, total and reduced, GSH, Cys
levels, and plasma GSH peroxidase type-3 (GPx-3) activities],
oxidative stress [plasma free MDA (fMDA) and urinary 15-isopros-
tane-F2t (known as 8-epi-PGF2a) levels] and inflammatory
variables [plasma IL-6, IL-8, TNF-a, serum C-reactive protein
(CRP) concentrations, and urine levels of neopterin, a specific
marker of monocyte activation] were assessed in LVAD-patients
serially from pre-implant, and subsequently at 1, 7 and 30 days
since LVAD placement. Hemodynamic was assessed preoperatively
and daily up to first postoperative week by pulmonary artery
Swan-Ganz catheter. Right heart function was monitored by
assessment of right atrial pressure (RAP) and inotropic need
[15, 16]. Inotropic equivalent >10 [17] and/or RAP >10 mmHg were
criteria to assess right heart dysfunction [18].
The overall condition of the multi-organ function was daily
monitored according to the Sequential Organ Failure Assessment
(SOFA) system [19]. The SOFA system is a daily score from 0 to 4
assigned in proportion to the severity of functional deterioration
for each of six individual organ systems (cardiovascular, respira-
tory, hepatic, renal, neurological, and hemocoagulative). The aggre-
gate total SOFA (tSOFA) score was calculated by adding the scores
for each of the organ systems during the observation period [19].
In stable ESHF group, echocardiographic, haemodynamic and
clinical data were collected during hospitalization. Before haemo-
dynamic assessment, fasting venous blood and urine samples were
collected for biochemical determinations.
In all control subjects, after an overnight fast, venous blood
and urine samples were withdrawn for biochemical determina-
tions before echocardiographic assessment, and clinical data were
collected at admission.
The study conformed the principles outlined in the Declaration
of Helsinki and the study protocol was approved by local ethics
committee. All subjects gave written informed consent to partici-
pate to the study.
2.3. Redox state assessment
Blood reduced GSH level was determined by prompt acidificat-
ion of whole blood immediately after blood sample collection
according to method previously described [11]. As reduced GSH
levels in plasma are low (1–2%), the reduced GSH concentration
in whole blood can reflect GSH content inside the cellular fraction
of blood. Plasma reduced and total forms of Cys and blood total
GSH were determined according to methods validated in our labo-
ratory [11]. The total form of GSH measured in our study includes
the oxidized GSH, all conjugated forms of GSH (protein-bound GSH
and GSH-mixed disulfides), produced through oxidative processes
or thiol-disulfide exchange reactions, and reduced free GSH. Thiol
separation was performed by high-performance liquid chromatog-
raphy (HPLC) method (ProStar-Varian, Surrey, UK). GPx-3 activity
was determined in plasma samples stored frozen up to analysis
that was performed within 1 month from storage. GPx-3 activity
was measured as previously described using t-butyl hydroperoxide
(SIGMA, Steinheim, Germany) as substrate [20].
2.4. Oxidative stress
fMDA levels, the reactive non conjugated MDA form, were
determined by isocratic HPLC assay with fluorescence detection
(ChromSystemsGmbH, München, Germany). Urinary 8-epi-PGF2a
levels were measured by enzyme-linked immunosorbent assay
(Oxford Biomedical Research, Inc., Oxford, MI, USA).
2.5. Inflammation parameters
Plasma IL-6, IL-8, and TNF-a levels were measured according by
enzyme-linked immunosorbent assays (R&D Systems, Minneapo-
lis, MN, USA). Urinary neopterin levels were measured by an iso-
cratic HPLC method previously described [19] and normalized by
urine creatinine concentrations (Neo/Cr), while sCRP concentra-
tions were measured using a Roche/Hitachi 917 Analyzer by
high-sensitive immuno-nephelometric method (Roche Diagnostic
GmbH, Mannheim, Germany).
2.6. Statistical analysis
Data are expressed as median and interquartile range (I, III) or
frequency (percentage). Differences among patient groups were as-
sessed by nonparametric Kruskal–Wallis test for continuous vari-
ables and by Chi-square for categorical variables. Changes of the
redox and inflammatory parameters during the time were ana-
lyzed by non-parametric Friedman test; post-hoc analysis with
Wilcoxon Signed-Rank tests was conducted with a Bonferroni cor-
rection applied, resulting in a significance level set at P < 0.017. The
association between variables was tested by Spearman’s correla-
tion test. Data were analyzed using SPSS for Windows (Version
17.0, Chicago, IL).
3. Results
3.1. Clinical findings in LVAD recipients, stable ESHF patients and
controls
The clinical characteristics of LVAD recipients, at the
pre-implant time, stable ESHF patients and controls are described
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in Table 1. Median age of LVAD-recipients was comparable to those
of stable ESHF patients and controls. The cardiovascular risk factors
were comparable among the groups with the exception of dyslipi-
demia, more present in stable ESHF patients, and smoking history
among LVAD recipients. LV-impairment, as evaluated by echocar-
diographic measurements, was comparable between LVAD recipi-
ents and stable ESHF patients, however, NYHA class was more
advanced in the former (Table 1).
Besides optimal medical and electrical therapy for chronic heart
failure, terminal HF patients candidate to LVAD implantation were
treated with inotropic support, while controls with one or more
cardiovascular risk factors received specific treatment (Table 1).
Blood urea nitrogen, plasma creatinine and total bilirubine lev-
els were comparable between stable ESHF patients and LVAD-
recipients at pre-implant time; tSOFA score of LVAD-recipients,
at pre-implant time, was significantly higher with respect to those
of other groups (Table 1).
Cardiac index (CI) and RAP values were comparable between
stable ESHF patients and LVAD recipients [1.88 (1.76, 2.07) vs.
1.69 (1.37, 2.00) L/min/m2 of CI, respectively, p = 0.102; 7 (2, 9)
vs. 6 (4, 10) mmHg of RAP, respectively, p = 0.901] while pulmon-
ary capillary wedge pressure (PCWP) levels were lower in stable
ESHF patients with respect to LVAD recipients [16 (10, 24) vs. 26
(15, 31) mmHg, respectively, p = 0.046].
3.2. Redox, oxidative and inflammatory states in LVAD recipients at
baseline, stable ESHF patients and controls
Plasma total Cys levels were higher, while blood and plasma to-
tal GSH levels were lower in LVAD recipients, at pre-implant time,
with respect to controls (Table 2). In LVAD recipients the blood re-
duced GSH levels and blood reduced to total GSH (r/tGSH) ratio, an
index of GSH bioavailability, were lower with respect to other
groups. The GPx-3 activities were higher in LVAD recipients with
respect to other groups (Table 2).
The LVAD recipients showed higher plasma fMDA levels with
respect to other groups and higher urinary 8-epi-PGF2a concentra-
tions only with respect to controls (Table 2).
Plasma IL-6, IL-8 and serum CRP levels were higher in LVAD
recipients with respect to other groups, while urinary Neo/Cr levels
were higher in LVAD recipients only with respect to controls. Plas-
ma TNF-a levels in LVAD recipients were not significantly different
with those of stable ESHF patients (Table 2).
3.3. Effect of LVAD implant on hemodynamic and clinical profile
Median duration of ICU stay of LVAD recipients was 14 (11,
20) days, ranging from 5 to 40 days. LVAD implantation improved
CI and reduced PCWP with respect to pre-implant hemodynamic
condition (Table 3). RAP values during first postoperative week
did not change compared to pre-implant condition, signs of right
heart failure were present in 11 patients only during first postop-
erative week.
The main morbid events occurred during early phase of
mechanical assistance are described in Table 4. During first
postoperative week, 14 patients showed elevated levels of serum
creatinine [1.35 (1.36, 1.45) mg/dL of serum creatinine in patients
with signs of renal dysfunction at 1 week], still observable in five
patients after 1 month [1.40 (1.34, 1.65) mg/dL], while 19 patients
present signs of hepatic dysfunction [6.73 (2.48, 9.63) mg/dL of
serum total bilirubine in patients with signs of hepatic dysfunction
at 1 week], still persistent in seven patients after 1 month [1.88
(1.61, 2.38) mg/dL]. Likewise, white blood cells increased during
first postoperative week (20/23 patients), but significantly
decreased after 1 month at values comparable to those of pre-
implant time (Table 3). During ICU stay, only two patients
Table 1
Clinical and echocardiographic parameters among LVAD-recipients, stable ESHF patients and controls.
Controls (n = 20) Stable ESHF patients (n = 22) LVAD recipients at pre-implant
time (n = 23)
P value for group
Age, years 51 (34, 63) 56 (49, 60) 51 (45, 61) 0.300
Male gender, n (%) 14 (70) 20 (91) 22 (96) 0.038
Hypertension, n (%) 8 (40) 6 (27) 5 (22) 0.409
Hyperlipidemia, n (%) 5 (25) 12 (55) 5 (22) 0.040
Diabetes, n (%) 5 (25) 4 (18) 5 (22) 0.865
History of smoking, n (%) 2 (10) 3 (14) 9 (39) 0.037
Etiology, n (%) 1.000
IDC – 15 (68) 16 (70)
ICM – 7 (32) 7 (30)
NYHA class <0.001
III – 15 (68) 2 (9)
IV – 7 (32) 21 (91)
LVEF, % 65 (63, 69)*,§ 27 (19, 33) 23 (18, 25) <0.001
LVEDV, mL 88 (76, 108)*,§ 186 (151, 289) 263 (181, 345) <0.001
LVEDD, mm 46 (42, 48)*,§ 67 (61, 75) 70 (60, 78) <0.001
Treatments, n (%)
ACEi + ATII 5 (25%) 16 (73%) 16 (70%) 0.002
Beta-blocker 2 (10%) 19 (86%) 13 (57%) <0.001
Statins 2 (10%) 10 (46%) 4 (17%) 0.017
Diuretics 1 (5%) 21 (96%) 23 (100%) <0.001
Inotropic therapy – – 17 (74%)
Creatinine, g/dL 0.90 (0.84, 0.98) 1.08 (0.90, 1.22) 1.02 (0.84, 1.36) 0.060
BUN, mg/dL 40 (34, 47)§ 48 (41, 65) 46 (35, 63) 0.045
t-Bil, mg/dL 0.51 (0.33, 0.69)*,§ 1.27 (0.66, 1.99) 1.43 (0.63, 2.10) <0.001
tSOFA-score, n 0 (0, 0)*,§ 2 (1, 2)* 5 (3, 7) <0.001
Data are expressed as median and interquartile range (I, III) or number (percentage). ACEi, ACE inhibitor; ATII, angiotensin II receptor antagonists; t-Bil, total bilirubin; BUN,
blood urea nitrogen; IDC, idiopathic dilated cardiomyopathy; ICM, ischemic cardiomyopathy; LVEDV, left ventricular end-diastolic volume; LVEDD, left ventricular end-
diastolic diameter; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; tSOFA, total Sequential Organ Failure Assessment.
* p < 0.05 vs. LVAD recipients by post-hoc test with Bonferroni correction.
§ p < 0.05 vs. stable ESHF patients by post-hoc test with Bonferroni correction.
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experienced infections because of decubitus wound. No patient
with infections was present at 1 month.
Pre-implant tSOFA-score, index of multi-organ function grade,
worsted during first postoperative week, but significantly de-
creased after 1 month of MCS (Table 3), with lower tSOFA-score
with respect to those of stable ESHF-patients [0 (0, 1) vs. 2 (1, 2),
p = 0.025].
3.4. Changes of redox state and oxidative stress after LVAD
implantation
Plasma total Cys, GSH and blood total GSH levels decreased dur-
ing the first month of MCS (Table 5), the former decreased to levels
comparable to controls (p = 0.513). Blood and plasma r/tGSH ratios
increased during first month of LVAD support, while GPx-3 activi-
ties decreased following LVAD implantation (Table 5).
Levels of plasma fMDA and urinary 8-epi-PGF2a remained un-
changed during the first month of MCS (Table 5).
3.5. Post-LVAD inflammatory changes
All inflammatory variables increased during the first week of
MCS, with the exception for TNF-a levels (Table 5), but at 1 month,
Table 3
Haemodynamic and clinical changes after LVAD implantation.
Pre-implant 24 PL hours 1 PL week 1 PL month P value for time
CI, L/min/m2 1.69 (1.37, 2.00) 2.75 (2.25, 3.48)* 2.95 (2.53, 3.85)* nd <0.001
PCWP, mmHg 26 (15, 31) 10 (9, 17)* 10 (8, 14)* nd 0.037
RAP, mmHg 6 (4, 10) 8 (7, 10) 7 (5, 9) nd 0.090
SvO2, % 54 (46, 61) 73 (69, 80) 70 (66, 80) nd 0.023
Diuretics, n (%) 23 (100) 9 (39)* 10 (44)* 4 (17)* <0.001
Inotropic eq, n 7 (0, 10) 8 (5, 18)* 3 (1, 10) 0 (0, 0)* <0.001
tSOFA-score, n 5 (3, 7) 7 (6, 9)* 7 (4, 9)* 0 (0, 1)* <0.001
Creatinine, g/dL 1.02 (0.84, 1.36) 1.35 (0.87, 2.01)* 1.00 (0.80, 1.35) 0.94 (0.62, 1.14)* <0.001
WBC, 109/L 8.9 (8.2, 11.6) 15.6 (12.7, 19.9)* 14.5 (12.3, 16.3)* 7.5 (6.3, 9.4) <0.001
Data are expressed as median and interquartile range (I, III) or number (percentage). CI, cardiac index; PCWP, pulmonary capillary wedge pressure; PL, post-LVAD; RAP, right
atrial pressure; SvO2, mixed venous oxygen saturation; tSOFA, total Sequential Organ Failure Assessment; WBC, white blood cells.
* p < 0.05 vs. pre-implant by post-hoc test with Bonferroni correction.
Table 2
Redox, oxidative stress and inflammatory parameters among LVAD recipients, stable ESHF patients and controls.
Controls (n = 20) Stable ESHF patients (n = 22) LVAD recipients at pre implant time (n = 23) P value for group
Redox state
r-Cyspl, lmol/L 8.43 (5.93, 10.58) 9.05 (7.13, 12.22) 9.61 (7.00, 11.50) 0.361
t-Cyspl, lmol/L 239 (205, 258)*,§ 313 (282, 383) 316 (258, 358) <0.001
r-GSHpl, lmol/L 2.04 (0.46, 2.65) 1.06 (0.68, 1.46) 1.73 (1.07, 2.28) 0.071
t-GSHpl, lmol/L 6.02 (4.95, 6.75)*,§ 3.18 (2.28, 4.45) 3.68 (2.78, 5.66) <0.001
r-GSHbl, lmol/L 758 (585, 948)*,§ 557 (479, 725)* 384 (315, 500) <0.001
t-GSHbl, lmol/L 968 (814, 1168)* 891 (781, 997) 790 (666, 915) 0.006
r/tGSHpl 0.337 (0.083, 0.468)* 0.321 (0.231, 0.427) 0.464 (0.343, 0.631) 0.016
r/tGSHbl 0.736 (0.646, 0.904)* 0.668 (0.518, 0.793)* 0.477 (0.418, 0.641) <0.001
GPx-3, IU/L 621 (540, 703)* 561 (506, 662)* 780 (587, 981) 0.003
Oxidative stress
fMDA, lmol/L 0.15 (0.11, 0.19)* 0.17 (0.13, 0.20)* 0.24 (0.13, 1.06) 0.086
8-epiPGF2t/Cr, ng/mg 1.70 (0.22, 2.49)* 1.87 (1.66, 3.00) 3.49 (0.92, 9.82) 0.045
Inflammatory parameters
IL-6, pg/mL 0.53 (0.0, 0.69)*,§ 1.97 (0.91, 6.69)* 12.8 (3.60, 37.2) <0.001
IL-8, pg/mL 2.95 (2.50, 4.72)* 4.40 (3.25, 7.43)* 7.80 (5.50, 11.3) <0.001
TNF-a, pg/mL 1.25 (0.60, 9.88)§ 10.6 (4.68, 18.5) 7.63 (4.55, 12.6) 0.012
CRP, mg/dL 0.20 (0.10, 0.40)* 0.40 (0.18, 0.63)* 2.20 (0.40, 3.82) <0.001
Neo/Cr, lmol/mmoL 0.12 (0.10, 0.21)*,§ 0.25 (0.15, 0.44) 0.37 (0.28, 0.71) <0.001
Data are expressed as median and interquartile range (I, III). Bl, Blood; CRP, C-reactive protein; Cys, cysteine; GSH, glutathione; GPx-3, glutathione peroxidase type-3; IL,
interleukin; fMDA, free malondialdehyde; Neo/Cr, neopterin to creatinine levels ratio; pl, plasma; r, reduced; t, total.
* p < 0.05 vs. LVAD recipients by post-hoc test with Bonferroni correction.
§ p < 0.05 vs. stable ESHF patients by post-hoc test with Bonferroni correction.
Table 4
Morbid events during early phase of LVAD support.
LVAD patients
Bleeding
Requiring surgery 1 (4)
Requiring >2 PRBC units 20 (87)
Hemorrhagie 7 (30)
Embolism 1 (4)
Arrhytmias
Atrial 4 (17)
Ventricular 3 (13)
Ventricular tachycardia 3 (13)
Infection
Sepsis 0 (0)
Local nondevice-related infection 2 (9)
SIRS 2 (9)
Respiratory failure 8 (35)
Renal failure 14 (61)
Hepatic dysfunction 19 (83)
Right heart failure 11 (48)
TIA 1 (4)
Psychological 3 (13)
Other neurological 0 (0)
Data are expressed as number (percentage). PRBC, packed red blood cells; SIRS,
systemic inflammatory response syndrome; TIA, transient ischemic attack.
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their levels returned comparable to pre-implant values. Differ-
ently, urinary Neo/Cr levels progressively increased during LVAD
support with higher levels at 1 month with respect to pre-implant
values (Table 5).
3.6. Correlations with tSOFA-score and with duration of ICU stay in
LVAD-patients
Among biomarkers, tSOFA-score was positively correlated with
plasma IL-6 (R = 0.64, p < 0.0001), IL-8 (R = 0.54, p < 0.0001), and
serum CRP (R = 0.63, p < 0.0001) levels.
On the other hand, duration of ICU stay of LVAD patients was
positively correlated with tSOFA score, assessed both at pre-
implant time (R = 0.57, p = 0.005) and at first postoperative week
(R = 0.82, p < 0.0001). Among biomarkers, duration of ICU stay
was positively correlated with pre-implant levels of plasma IL-6
and serum CRP (Fig. 1). Likewise plasma IL-8 levels, measured after
24 h following LVAD implantation, positively correlated with
duration of ICU stay (R = 0.66, p = 0.001).
3.7. Outcomes
At 1 year following LVAD implantation, eight of the 23 enrolled
LVAD patients were bridged to HT, four died while on the device
[three died because of cerebral hemorrhage and one because of
multi-organ failure syndrome (MOFS)] and one was weaned off de-
vice due to cardiac recovery (after 192 days from LVAD implanta-
tion). The other patients were awaiting for HT.
4. Discussion
The present study shows that advanced HF patients are charac-
terized by a worsening of redox state and systemic inflammation,
with concomitant increase of oxidative stress and monocyte acti-
vation. These alterations are more aggravate in ESHF patients with
hemodynamic instability needing an LVAD implantation as BTT,
when compared to stable ESHF patients. However, the severity of
inflammatory milieu and oxidative stress present in LVAD recipi-
ents persist after 1 month of LVAD support, with further activation
of monocytes, even though adequate hemodynamic recovery and
amelioration of multi-organ function by LVAD implant. Early post-
operative changes of multi-organ function resulted related with IL-
6 and IL-8 level flotation, while duration of ICU stay related with
pre-implant IL-6 and CRP levels.
Increasing evidences indicate oxidative stress and altered
inflammatory processes as potential mechanisms involved in the
pathogenesis and clinical course of chronic HF [7, 8, 21]. Elevated
TNF-a and IL-6 levels were reported in patients who required
Table 5
Redox, oxidative stress and inflammatory parameters after LVAD implantation.
Pre-implant 24 PL hours 1 PL week 1 PL month P value for time
Redox state
r-Cyspl, lmol/L 9.61 (7.00, 11.50) 11.80 (8.81, 16.46)* 9.02 (7.60, 10.40) 9.20 (7.90, 11.20) 0.003
t-Cyspl, lmol/L 316 (258, 358) 216 (191, 304)* 274 (230, 314)* 240 (205, 314)* <0.001
r-GSHpl, lmol/L 1.73 (1.07, 2.28) 1.76 (1.33, 2.16) 1.66 (1.15, 2.91) 1.62 (1.30, 2.51) 0.168
t-GSHpl, lmol/L 3.68 (2.78, 5.66) 3.64 (2.81, 5.13) 2.31 (1.79, 3.99) 2.81 (1.64, 3.63)* 0.034
r-GSHbl, lmol/L 384 (315, 500) 351 (295, 453) 374 (310, 433) 421 (307, 592) 0.241
t-GSHbl, lmol/L 790 (666, 915) 754 (673, 856) 630 (542, 736)* 627 (548, 734)* <0.001
r/tGSHpl 0.464 (0.343, 0.631) 0.444 (0.337, 0.673) 0.642 (0.378, 0.894)* 0.716 (0.494, 0.970)* 0.003
r/tGSHbl 0.477 (0.418, 0.641) 0.499 (0.404, 0.566) 0.587 (0.490, 0.667) 0.685 (0.557, 0.799)* <0.001
GPx-3, IU/L 780 (587, 981) 647 (555, 832)* 711 (511, 908) 627 (450, 772)* 0.003
Oxidative stress
fMDA, lmol/L 0.24 (0.13, 1.06) 0.35 (0.16, 0.99) 0.50 (0.19, 0.87) 0.43 (0.18, 1.30) 0.398
8-epiPGF2t/Cr, ng/mg 3.49 (0.92, 9.82) 2.89 (0.74, 6.01) 4.43 (1.24, 16.80) 2.85 (1.44, 8.48) 0.235
Inflammatory parameters
IL-6, pg/mL 12.8 (3.6, 37.2) 376.5 (177.4, 590.4)* 61.0 (30.3, 123.3) 20.2 (8.2, 30.6) <0.001
IL-8, pg/mL 7.8 (5.5, 11.3) 20.1 (11.7, 35.9)* 19.3 (16.0, 36.5)* 10.4 (8.4, 14.0) <0.001
TNF-a, pg/mL 7.63 (4.55, 12.9) 9.75 (3.00, 19.8) 6.50 (3.08, 12.8) 9.95 (6.75, 13.3) 0.682
CRP, mg/dL 2.2 (0.4, 3.8) 16.7 (11.6, 22.4)* 10.2 (4.7, 13.9)* 2.4 (1.3, 3.6) <0.001
Neo/Cr, lmol/mmol 0.37 (0.28, 0.71) 0.49 (0.35, 0.74) 0.74 (0.53, 1.02)* 0.97 (0.49, 1.71)* <0.001
Data are expressed as median and interquartile range (I, III). For abbreviations see Tables 2 and 3.
* p < 0.05 vs. pre-implant by post-hoc test with Bonferroni correction.
Fig. 1. Correlations of duration of ICU stay with pre-implant plasma IL-6 (A), and serum CRP (B) levels in LVAD patients.
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LVAD assistance compared with patients with less severe HF [22].
In agreement with these findings, in our ESHF patients needing
LVAD implantation the levels of pro-inflammation cytokines were
markedly higher when compared to patients with stable ESHF.
Only TNF-a levels were comparable between patients with differ-
ent severity of disease. Our LVAD recipients showed even elevated
levels of IL-8, a neutrophil- and macrophage-attracting chemokine
on endothelial cells, and neopterin, a pteridine-derivative pro-
duced by activated monocytes. These data support that monocyte
activation is implicated in the hemodynamic instability of end-
stage phase of HF. Moreover, also the grade of systemic oxidative
stress was markedly elevated in LVAD recipients compared to sta-
ble ESHF patients. In particular, systemic oxidative stress seems to
involve membrane damage since isoprostane 8-epiPGF2 is a prosta-
glandin-like compound, synthesized through the free radical cata-
lyzed peroxidation of arachidonic acid, while MDA is a marker of
membrane damage due to peroxidation of polyunsaturated lipids.
In addition, our LVAD recipients showed even a worsening of sys-
temic redox state with lower GSH bioavailability with respect to
stable ESHF patients. Altogether these findings indicate that end-
stage HF disarrangement (acute hemodynamic instability and mul-
ti-organ function collapse), that addressed to LVAD placement, is
properly characterized by intensification of oxidative stress and
pro-inflammatory milieu.
The LVAD implantation has become an effective therapeutic
option for hemodynamic recovery of advanced HF patients, but
post-implant morbid events impact on successful outcome and
on clinical course of patients [1]. Several studies have focused in
findings the right indications and timing for LVAD implant to
minimize postoperative adverse events, mainly evaluating clinical
and hemodynamic variables [23–26]. The MCS seems to be associ-
ated to a better prognosis, even as functional recovery, when
LV-unloading, attenuating LV wall stress, and the restoration of a
normal neurohormonal milieu are obtained [3]. The inflammatory
network activated following LVAD implantation have been
reported to play an important role in the development of MOFS
[19, 27], supporting that the attenuation or normalization of
inflammatory state by hemodynamic recovery is a condition for
favorable outcome. In this context the search for useful systemic
biomarkers to predict the main complications that occur during
MCS is generating interest.
In our patients supported by LVAD, the high pre-implant levels
of inflammatory mediators further increased during the first week
of LVAD support, with marked IL-6 and CRP levels, probably due to
the impact of surgery and cardiopulmonary by-pass. Moreover, the
activation of IL-6–CRP pathway probably stimulates the increased
expression of chemokine IL-8 and the further activation of mono-
cytes, as evidenced by profile of neopterin during the first month
of LVAD. Indeed neopterin is a known pteridine mainly synthesized
by macrophages and monocytes at levels reflecting their degree of
activation [28]. In this phase of LVAD support these elevated levels
of pro-inflammatory mediators might promotes vascular inflam-
mation, a mechanism also demonstrated in animal models [29],
favoring the development of morbid events. The relationship found
between tSOFA score and IL-6 levels suggests a correlation
between IL-6-dependent signaling pathways, their degree of acti-
vation and change of overall organ function during MCS. Indeed,
in our LVAD recipients, the early postoperative phase was charac-
terized by deterioration of multi-organ function, as evidenced by
high tSOFA score, and complications observed during ICU stay.
Moreover, the length of stay in ICU, that reflects the clinical course,
was found related with pre-implant levels of IL-6, CRP, tSOFA score
and, at 24 post-LVAD hours, also with the levels of IL-8. Although
requiring validation in a larger series, these data support a role
of inflammatory milieu and grade of multi-organ dysfunction, at
pre-implant, and of consequent inflammatory post-LVAD response
on the onset of morbid events and their severity, factors that
together might affect the duration of hospitalization. Likewise,
postoperative vasodilatation and hemodynamic instability were
observed also in patients undergoing elective coronary artery by-
pass grafting with increased circulating levels of IL-6 and IL-8 [30].
In a previous study [19] we reported that LVAD patients who
died because of adverse MOFS during early MCS showed levels of
pro-inflammatory cytokines and tSOFA score much higher than
complication-free LVAD-patients. Altogether these data suggest
that the severity of end-organ dysfunction reflects the grade of
inflammatory response. Patients with less aggressive inflammatory
response showed minor and transitory complications, as observed
in our patient series.
After 1 month of LVAD support, the inflammatory status and
oxidative stress in our patients maintain levels comparable to those
pre-intervention, representing an unfavorable condition potentially
affecting the long-term outcome. Moreover, the progressive incre-
ment of monocyte activation, as found in our LVAD-patients, might
contribute for late thromboembolic events, a condition that might
be enhanced also by pro-inflammatory stimuli [31]. Note that at
the same timemulti-organ function was already improved to phys-
iological condition with respect to pre-implant time. Our findings
support the hypothesis that LV-unloading and hemodynamic
recovery after 1 month of MCS do not attenuate the levels of pro-
inflammatory cytokines and oxidative stress implicated in the ter-
minal phase of HF. These data are in agreement with previous re-
port that found TNF-a and IL-6 levels after 3 months of MCS
comparable with those at pre-implant time [32]. Only circulating
redox state was ameliorated by LVAD. Indeed, increase in GSH bio-
availability, normalization of Cys levels and decrease of GPx-3
activity, observed during 1 month of MCS, are evidences of the
establishment of the partial restoration of a balanced redox state.
The sources of cytokine production in HF are likely multiple and
include the immune system, peripheral tissues, and the failing
heart itself. The amelioration of multi-organ function observed at
1 month by LVAD seems to exclude an involvement of peripheral
tissues as sources of cytokine and production of reactive oxygen
species. The decrease of myocardial TNF-a in LVAD patients that
experienced cardiac functional recovery suggests the heart as a
source of inflammatory activation and its reduction as signal asso-
ciated with the inverse remodeling [33]. However, true myocardial
recovery is very uncommon and, when it occurs, it takes weeks to
months to reach a level that allows LVAD removal. Only in one of
our LVAD patients, hemodynamic improvement allowed for
weaning from the device, but after long-term MCS. Therefore, the
persistence of elevated levels of pro-inflammatory cytokine and
of oxidative stress at 1 month is probably imputable to failing
heart and immune system, as potential sources of production of
inflammatory cytokines and reactive oxygen species, not still al-
tered by early phase of LVAD support. However, future studies
are recommended to evaluate the effect of LVAD implant on
inflammation and oxidative stress in a longer time of ventricular
unloading.
It is noteworthy that levels of TNF-a, differently from those of
the other inflammatory mediators, were unchanged during the
overall period of the first month of LVAD. This finding suggests that
circulate TNF-a levels, in LVAD patients, are not affected by
peripheral tissues or immune system potentially implicated into
transitory and reversible multi-organ dysfunction, as observed in
the early phase of LVAD support.
5. Conclusions
In terminal ESHF patients, hemodynamic recovery, LV unload-
ing and amelioration of multi-organ function obtained following
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1 month of MCS did not improve the grade of oxidative stress and
severe inflammatory milieu pre-existent at pre-implant. Pre-im-
plant levels of IL-6 may contribute to worsening of multi-organ
function during early phase of MCS, and to a worse duration of
ICU stay, as well as the postoperative change of IL-8. Thus, further
studies with longer monitoring period are needed to evaluate
whether and to what degree LVAD reduces both oxidative stress
and expression of pro-inflammatory cytokines, potential signs of
adverse remodeling.
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